ACTH 1-17 effects in acute myeloid leukemia.
We conducted a double blind randomized clinical study with 100 micrograms i.v. ACTH 1-17 versus placebo in 40 consecutive acute myelocytic leukemia patients (AML). The same regimen 3 + 7 schedule, employing daunorubicin (DNR) associated with cytosine-arabinoside (ARA-C), was applied as remission induction therapy to all patients. Prednisone therapy was performed as necessary. Twenty patients, receiving ACTH 1-17, were compared with 20 other patients receiving placebo in regard to remission rate, hemorrhagic and infective complications, remission duration and survival. No significant difference was observed between the 2 groups for all parameters taken into consideration. The two year actuarial curves of remission duration and survival showed a trend in favour of the ACTH 1-17 group. It needs a longer follow-up to evaluate if ACTH 1-17 will represent an effective adjuvant of the induction chemotherapy for the long-term control of the acute myelocytic leukemia.